Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

Inclusion Criteria: * Wish to conceive; * Oligomenorrhea (cycle length \>=41 days) or amenorrhea (no menstrual cycle for \>6 months); * Body Mass Index (BMI) \>=18 and \<=32 kg/m\^2; * Serum FSH levels within normal limits (1-10 IU/L); * Normal serum prolactin and thyroid stimulating hormone (TSH) levels; * Progestagen induced withdrawal bleeding or spontaneous menstrual bleeding; Exclusion Criteria: * Tumours of the ovary, breast, uterus, pituitary or hypothalamus; * Pregnancy or lactation; * Undiagnosed vaginal bleeding; * Ovarian cysts or enlarged ovaries not related to polycystic ovarian disease (PCOD); * Any ovarian and/or abdominal abnormality interfering with ultrasound examination; * Malformations of the sexual organs incompatible with pregnancy; * Clomiphene resistance with documented anovulation (treated with 150 mg clomiphene for five days and no ovulation); * Treatment with metformin, gonadotropins, or GnRH analogs within 90 days prior to the start of Org 36286 treatment; * Treatment with clomiphene citrate within 42 days prior to the start of Org 36286 treatment; * Alcohol or drug abuse within the 12 months preceding signing of informed consent; * Any clinically relevant abnormal laboratory value; * Hypersensitivity to any of the substances in Org 36286; * Hypersensitivity to Orgalutran® or any of its components; * Use of any investigational drugs during 90 days before screening or previous participation in this trial.